Directory
Agueda Martinez Barriocanal

Agueda Martinez Barriocanal

Degree: PhD

973702484
amartinez(ELIMINAR)@irblleida.cat

Publications

  • Dopeso, H; Rodrigues, P; Cartón-García, F; Macaya, I; Bilic, J; Anguita, E; Jing, L; Brotons, B; Vivancos, N; Beà, L; Sánchez-Martín, M; Landolfi, S; Hernandez-Losa, J; Cajal, SRY; Nieto, R; Vicario, M; Farre, R; Schwartz, S Jr; van Ijzendoorn, SCD; Kobayashi, K; Martinez-Barriocanal, A; Arango, D

    RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis

    iScience 27 109400-109400. .

    [doi:10.1016/j.isci.2024.109400]

  • Matos, AI; Peres, C; Carreira, B; Moura, LIF; Acurcio, RC; Vogel, T; Wegener, E; Ribeiro, F; Afonso, MB; Santos, FMF; Martínez-Barriocanal, A; Arango, D; Viana, AS; Góis, PMP; Silva, LC; Rodrigues, CMP; Graca, L; Jordan, R; Satchi-Fainaro, R; Florindo, HF

    Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors

    Advanced Science 10 -. .

    [doi:10.1002/advs.202300299]

  • Carton-Garcia, F; Brotons, B; Anguita, E; Dopeso, H; Tarragona, J; Nieto, R; Garcia-Vidal, E; Macaya, I; Zagyva, Z; Dalmau, M; Sanchez-Martin, M; van Ijzendoorn SCD; Landolfi, S; Hernandez-Losa, J; Schwartz S Jr; Matias-Guiu, X; Ramón Y Cajal S; Martinez-Barriocanal, A; Arango, D

    Myosin Vb as a tumor suppressor gene in intestinal cancer.

    ONCOGENE 41 5279-5288. .

    [doi:10.1038/s41388-022-02508-2]

  • Fourniols, T; Maggio, V; Rafael, D; Colaco, A; García Vidal E; Lopes, A; Schwartz, S; Martinez-Barriocanal, A; Preat, V; Arango, D

    Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.

    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 171 39-49. .

    [doi:10.1016/j.ejpb.2021.10.017]

  • Bazzocco S; Dopeso H; Martínez-Barriocanal Á; Anguita E; Nieto R; Li J; García-Vidal E; Maggio V; Rodrigues P; de Marcondes PG; Schwartz S Jr; Aaltonen LA; Sánchez A; Mariadason JM; Arango D

    Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis.

    Clinical Epigenetics 13 88-88. .

    [doi:10.1186/s13148-021-01070-0]

  • Montanuy, H; Martinez-Barriocanal, A; Antonio Casado J; Rovirosa, L; Ramirez, MJ; Nieto, R; Carrascoso-Rubio, C; Riera, P; Gonzalez, A; Lerma, E; Lasa, A; Carreras-Puigvert, J; Helleday, T; Bueren, JA; Arango, D; Minguillon, J; Surralles, J

    Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.

    CLINICAL CANCER RESEARCH 26 3044-3057. .

    [doi:10.1158/1078-0432.CCR-19-1625]

  • Martinez-Barriocanal, A; Arango, D; Dopeso, H

    PVT1 Long Non-coding RNA in Gastrointestinal Cancer.

    Frontiers in oncology 10 38-38. .

    [doi:10.3389/fonc.2020.00038]

  • Matos AI; Carreira B; Peres C; Moura LIF; Conniot J; Fourniols T; Scomparin A; Martínez-Barriocanal Á; Arango D; Conde JP; Préat V; Satchi-Fainaro R; Florindo HF

    Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer.

    JOURNAL OF CONTROLLED RELEASE 307 108-138. .

    [doi:10.1016/j.jconrel.2019.06.017]

Projects

  • Turning drug-induced senescence into a novel therapeutic opportunity for colorrectal cancer treatment
  • Nueva aproximación terapéutica para el cáncer colorectal.
  • EPH Receptor Signaling in Endometrial Cancer
  • Antioxidant treatment as a novel therapeutic option for microvillus inclusion disease. ARMED
  • Nueva estrategia terapéutica para ael cáncer gástrico basada en la modulación de la señalización de RHOA
  • Desarrollo de nanosistemas de marcaje de CXCR4 mediante radiosondas para la imagen molecular de células tumorales y del microambiente tumoral
  • Identificación de nuevos biomarcadores de respuesta a los compuestos regorafenib y TAS-102 en pacientes con cáncer colorrectal.
  • Targeting tumor microevironment by a translational multivalent nanomedicine: towards an effective anticancer combination immunotherapy